diabetestalk.net

Humalog Junior Kwikpen Ndc

Ndc 0002-7714 Humalog Junior Kwikpen

Ndc 0002-7714 Humalog Junior Kwikpen

HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)].Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen.Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump.Do NOT transfer HUMALOG U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)].Do NOT perform dose conversion when using either the HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed.Do NOT mix HUMALOG U-200 with any other insulins.Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump).Do NOT administer HUMALOG U-200 intravenously. Subcutaneous Injection: HUMALOG U-100 or U-200Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. Continuous Subcutaneous Infusion (Insulin Pump): HUMALOG U-100 ONLYDo NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump. Administer HUMALOG U-100 by continuous subcutaneous infusion into the subcutaneous tissue of the abdominal wall. Rot Continue reading >>

Ndc Code 0002-7714-61 Humalog Junior Kwikpen Insulin Lispro

Ndc Code 0002-7714-61 Humalog Junior Kwikpen Insulin Lispro

All contents of this website are provided on an "as is" and "as available" basis without warranty of any kind. The contents of the National Drug Codes List website are provided for educational purposes only and are not intended in any way as medical advice, medical diagnosis or treatment. Reliance on any information provided by the National Drug Codes List website or other visitors to this website is solely at your own risk. Many of Over the Counter drugs are not reviewed by the FDA but they might be marketed to the public if the product complies with the applicable rules and regulations. The information in this website is intended for healthcare providers and consumers in the United States. The absence of a warning or notice for a given drug or drug combination is not indication that the drug or drug combination are safe, appropriate or effective for any given patient. If you have questions or concerns about the substances you are taking, check with your healthcare provider. If you think you may have a medical emergency, please call your doctor or 911 immediately. Continue reading >>

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

0002-7714 : Humalog 100 [iu]/ml Subcutaneous Injection, Solution

0002-7714 : Humalog 100 [iu]/ml Subcutaneous Injection, Solution

0002-7714 : Humalog 100 [Iu]/Ml Subcutaneous Injection, Solution 0002-7714-59: 5 SYRINGE IN 1 CARTON (0002771459) > 3 ML IN 1 SYRINGE (0002771401) 0002-7714-61: 1 SYRINGE IN 1 CARTON (0002771461) > 3 ML IN 1 SYRINGE Byetta give leg pain. Do Novolog have muscle and pain sideaffects. I want to try Novolog pen. ## Byetta should not cause... 1reply Notice: The MedsChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us . Join over 75,000 subscribers and we'll send you a Drugs Top Prescription Drugs Drug Categories National Drug Code Database Half Life Calculator Recent FDA Approvals Current Health News What are people searching? Generic Me Alprazolam Pain White Pill Blue Specks No Imprint Antibiotics Pills Difference Between Dytor Plus Search Support Vitamin B C And E Can Be Take Together G037 Citalopram Hydrobromide 20 Mg Anneal 3 More Recent Topics ... This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer . Site content is Copyright 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 11 May 2018. Copyright 2005-2018 All Rights Reserved. MedsChat and The People's Medicine Community are registe Continue reading >>

Humalog - Instruction, Prescriptions, Dosage, Side Effects, Interactions

Humalog - Instruction, Prescriptions, Dosage, Side Effects, Interactions

HUMALOG (insulin lispro injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin. HUMALOG has the following primary structure: HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG U-100 contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. Each milliliter of HUMALOG U-200 contains insulin lispro 200 units, 16 mg glycerin, 5 mg tromethamine, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.046 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. Insulin Initiation And Intensification Of Glucose Control Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy Continue reading >>

0002-7714 Ndc - Humalog (insulin Lispro)

0002-7714 Ndc - Humalog (insulin Lispro)

0002-7714 NDC - HUMALOG (INSULIN LISPRO) 5 SYRINGE in 1 CARTON (0002-7714-59) > 3 mL in 1 SYRINGE (0002-7714-01) 1 SYRINGE in 1 CARTON (0002-7714-61) > 3 mL in 1 SYRINGE The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the Document Type field of the Structured Product Listing. The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product. The translation of the route code submitted by the firm, indicating route of administration. This is the date that the labeler indicates was the start of its marketing of the drug product. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls u Continue reading >>

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

Indications And Usage For Humalog

Indications And Usage For Humalog

Generic Name: insulin lispro Dosage Form: injection, solution Humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Dosage and Administration Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)]. Inspect Humalog visually before use. It should appear clear and colorless. Do not use Humalog if particulate matter or coloration is seen. Do NOT mix Humalog U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)]. Do NOT perform dose conversion when using any Humalog U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. Humalog U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. Humalog Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix Humalog U-200 with any other insulins. Do NOT administer Humalog U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer Humalog U-200 intravenously. Route of Administration Subcutaneous Injection: Humalog U-100 or U-200 Administer the dose of Humalog U-100 or Humalog U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. Humalog administered by subcutaneous injection should generally be used in regimens with an intermediate- or lon Continue reading >>

Preferred Drug List. Comprehensive. Updated April 2018

Preferred Drug List. Comprehensive. Updated April 2018

1 Comprehensive PREERRED DRUG LIST Updated April 2018 This ormulary is up to date through its date of publication, April Please notify IlliniCare Health at or (866) with any mistakes in the formulary. 2 Pharmacy Program IlliniCare Health is committed to providing the right drug coverage to our members. We work with providers and pharmacists to make sure we cover drugs used to treat many conditions and diseases. IlliniCare Health covers prescription and certain over-the-counter (OTC) medications when ordered by a network provider. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. The IlliniCare Health pharmacy program covers members in the HealthChoice Illinois plan. illing a Prescription You can have your prescriptions filled at a network pharmacy. At the pharmacy, you will need to give the pharmacist your prescription and your ID card. You can find a pharmacy that is in the IlliniCare Health network by using the ind a Provider tool on If you need help finding a pharmacy near you, call us at (toll-free)/ TTY: 771. There is no cost for covered drugs. If your medication is not on the preferred drug list or is on the preferred drug list but has limitations, you can: 1. Speak with your doctor about switching to a similar medication that is on the preferred drug list. 2. Request a prior authorization, or speak to your doctor about submitting a prior authorization for you. You or your doctor may do this by submitting the medication prior authorization form, found on Generic s Generic drugs have the same active ingredient and work the same as brand name drugs. When generic drugs are available, the brand name drug will not be covered without prior authorization. Spe Continue reading >>

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. The April, 2018 Medicare Part D plan formulary data (or drug list updates) includes the addition of 737 new National Drug Codes (NDCs) to the Medicare Part D program. These NDCs represent 486 different drugs, many with multiple strengths. There are so many new NDCs, that we have to split the list into 5 parts. This article will cover drugs starting with the letters D through H. Here are links to A-C , I-M , N-P , and Q-Z . Fifty-seven new NDC generic equivalents were added, including including DACTINOMYCIN [Cosmegen], DAPTOMYCIN [Cubicin], EFAVIRENZ [Sustiva], ELETRIPTAN HBR [Relpax], ESCITALOPRAM OXALATE [Lexapro],ESOMEPRAZOLE MAG [Nexium], ETHYNODIOL-ETH ESTRA [ZOVIA], ETODOLAC [LODINE], FENOFIBRATE [LIPOFEN], FENOFIBRIC ACID [TRILIPIX], FOSAMPRENAVIR [Lexiva], GLATIRAMER [Copaxone], Hepatitis B Surface Antigen Vaccine [Recombivax], Human-Bovine Reassortant Rotavirus Oral Vaccine [RotaTeq], HYDROXYPROGESTERONE [MAKENA], amongst others. See details in the chart below. As a reminder, the NDC uniquely identifies a particular manufacturer, drug-strength,and packaging combination. The NDC for your medication is often shownon your prescription bottle as an 11-digit code (see the charts below)or could be formatted as 00000-0000-00 where the first set of numbersidentifies the manufacturer, the second set of number identifies thedrug and strength, and the third set of numbers identifies thepackaging. New NDCs can be added to the Medicare Part D program for a numbe Continue reading >>

What Are The Possible Side Effects Of Insulin Lispro (humalog, Humalog Cartridge, Humalog Kwikpen, Humalog Pen)?

What Are The Possible Side Effects Of Insulin Lispro (humalog, Humalog Cartridge, Humalog Kwikpen, Humalog Pen)?

HUMALOG (insulin lispro) Injection DESCRIPTION HUMALOG® (insulin lispro injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin. HUMALOG has the following primary structure: HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG U-100 contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. Each milliliter of HUMALOG U-200 contains insulin lispro 200 units, 16 mg glycerin, 5 mg tromethamine, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.046 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. font size A A A 1 2 3 4 5 Next What is Type 2 Diabetes? The most common form of diabetes is type 2 diabetes, formerly called non-insulin dependent diabetes mellitus or "adult onset" diabetes, so-called because it typically develops in adults over age 35, though it can develop at any age. Type 2 diabetes i Continue reading >>

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Humalog KwikPen is a small, lightweight, prefilled insulin pen for patients with type 2 or type 1 diabetes who want a portable device. Humalog KwikPen should not be refrigerated after first use and can be taken just about anywhere. Patients can carry it in their purse, backpack, or pocket because it’s the size of a marker. Remind your patients to always carry an extra pen. In-use Humalog KwikPen should be stored at room temperature, below 86°F (30°C). Humalog KwikPen must be used within 28 days or be discarded, even if it still contains Humalog. Humalog U-100 KwikPen can be an easy-to-use, easy-to-inject prefilled pen option*14 Easy to set the dose*14 Easy to see the numbers*14 Easy to dial up and back down for dose selection*14 Easy to dispense maximum dose of 60 units*14 Allows patients or caregivers to discreetly deliver insulin To help patients and their caregivers learn how to inject using Humalog KwikPen, please click to access the Humalog U-100 KwikPen Instructions for Use. *Humalog KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin-naïve, 42 were currently administering insulin with a vial and syringe, and 52 were experienced insulin pen users. Pen needles for use with Humalog KwikPen Humalog KwikPen is suitable for use with Becton Dickinson (BD) needles (sold separately and may require a separate prescription). BD offers a comprehensive line of advanced protection products. For more information about BD pen needles, visit the BD Diabetes website for healthcare professionals. Pens and needles are for single-patient use only and should not be shared, even in healthcare facilities, as infection or disease can be spread from one person to another Continue reading >>

H - Medications And Drugs Listing - Page 17

H - Medications And Drugs Listing - Page 17

What are some things I need to know or do while I take House Dust Mite Allergen Extract? Tell all of your health care providers that you take house dust mite allergen extract. This includes your doctors, nurses, pharmacists, and dentists. This medicine will not help allergy signs get better if the signs are already pre... House dust mite allergen extract Sublingual Uses For house dust mite allergen extract Odactra is an allergen extract that is used to treat symptoms of allergic rhinitis, with or without conjunctivitis, caused by house dust mites. house dust mite allergen extract contains house dust mite allergen extract from Dermatophagoides far... This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy). Emollients are substances that soften and moisturize the skin and decreas... Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (includin... This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control c... How is this medicine (HPR Plus-MB HydroGel) best taken? Use this medicine as ordered by your doctor. Read all information given to you. Follow all instructions closely. Follow how to use as you have been told by the doctor or read the package insert. Prefilled syringes in patient with latex allergy Not recommended during pregnancy (safety not established) Syncope may occur, observe for 15 min after administr... Avoid Continue reading >>

Sanofi-aventis

Sanofi-aventis

Drug Manufacturer Pen Name Drug Drug NDC Number Do BD Pen Needles Fit?* Sample Bag of BD Pen Needles in Drug Starter Kits Place Where Drug Manufacturers Reference BD Needles Reference to BD Ultra-Fineâ„¢ Pen Needles Sanofi-Aventis Apidra® SoloStar® Apidra® 0088-2502-05 Yes N/A Package Insert Patient Instructions for use Patient Toll Free Phone Number "SoloStar® is compatible with all pen needles from Becton Dickinson and Company" Lantus® SoloStar® Lantus® 0088-2220-60 Yes N/A Package Insert User Manual, Device Page, Website "BD Ultra-Fineâ„¢ needles to be used in conjunction with SoloStar® and OptiClik® are sold separately and are manufactured by BD." "BD Ultra-Fineâ„¢ needles are compatible with SoloStar® . These are sold separately and are manufactured by BD." OptiClik® for Apidra® Apidra® 3mL Cartridge 0088-2500-52 Yes Yes User Manual Patient Checklist "Needles are available from BD Consumer Healthcare." "Prescription for BD pen needles." OptiClik® for Lantus® Lantus® 3mL Cartridge 0088-2220-52 Yes Yes User Manual, Patient Checklist, Lantus® Package Insert "Needles are available in different lengths and gauges from BD Consumer Healthcare." Amylin Pharmaceuticals & Eli Lilly and Company Byetta® Byetta® 66780-0210-07 66780-0210-08 Yes Yes Amylin Pharmaceuticals SymlinPenâ„¢ 60 & 120 Symlin ® 66780-155-02 66780-121-02 Yes Yes, 5mm Eli Lilly and Company HumaPen® Memoirâ„¢ Humalog® 3mL Cartridge 0002-7516-59 Yes Yes, 8mm User Manual, Website "HumaPen ® MEMOIRâ„¢ is suitable for use with Becton, Dickinson and Company insulin pen needles." HumaPen® LUXURAâ„¢ HD Humalog® 3mL Cartridge 0002-7516-59 Yes N/A, No Starter Kit Offered User Manual, Website "HumaPen ® LUXURAâ Continue reading >>

Dailymed - Humalog- Insulin Lispro Injection, Solution Humalog Kwikpen - Insulin Lispro Injection, Solution

Dailymed - Humalog- Insulin Lispro Injection, Solution Humalog Kwikpen - Insulin Lispro Injection, Solution

5.1 Never Share a HUMALOG KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges1, or Syringe Between Patients HUMALOG KwikPens, cartridges, and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed. Patients using HUMALOG vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 5.2 Hyper- or Hypoglycemia with Changes in Insulin Regimen Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions ( 5.3 )] or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )], or in patients who experience recurrent hypoglycemia. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose low Continue reading >>

More in diabetes